TRACLEER Drug Patent Profile

Which patents cover Tracleer, and what generic alternatives are available?

Tracleer is a drug marketed by Actelion and is included in two NDAs. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has twenty-eight patent family members in twenty-three countries.

The generic ingredient in TRACLEER is bosentan. There are nineteen drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the bosentan profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Tracleer

A generic version of TRACLEER was approved as bosentan by SUN PHARM on April 26^th, 2019.

Summary for TRACLEER

International Patents:	28
US Patents:	2
Applicants:	1
NDAs:	2
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for TRACLEER

Paragraph IV (Patent) Challenges for TRACLEER

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
TRACLEER	for Oral Suspension	bosentan	32 mg	209279	1	2019-02-08

US Patents and Regulatory Information for TRACLEER

TRACLEER is protected by two US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Actelion	TRACLEER	bosentan	TABLET, FOR SUSPENSION;ORAL	209279-001	Sep 5, 2017	AB	RX	Yes	Yes			Y
Actelion	TRACLEER	bosentan	TABLET;ORAL	021290-002	Nov 20, 2001	AB	RX	Yes	Yes
Actelion	TRACLEER	bosentan	TABLET, FOR SUSPENSION;ORAL	209279-001	Sep 5, 2017	AB	RX	Yes	Yes			Y
Actelion	TRACLEER	bosentan	TABLET;ORAL	021290-001	Nov 20, 2001	AB	RX	Yes	No

International Patents for TRACLEER

When does loss-of-exclusivity occur for TRACLEER?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Canada

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering TRACLEER around the world.

Country	Patent Number	Title	Estimated Expiration
Greece	3035162
Finland	112216
Norway	339781
Slovakia	279006
Norway	922323
Japan	2008540512
Hungary	T63152

Supplementary Protection Certificates for TRACLEER

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0526708	300097	Netherlands
0526708	CA 2002 00026	Denmark
0526708	02C0042	France		PRODUCT NAME: BOSENTAN MONOHYDRATE; NAT. REGISTRATION NO/DATE: EU/1/02/220/001 20020515; FIRST REGISTRATION: LI - 55841 20020228
0526708	SPC/GB02/030	United Kingdom		PRODUCT NAME: BOSENTAN 4-(1,1-DIMETHYLETHYL)-N-(6-(2-HYDROXYETHOXY)-5-(2-METHOXYPHENOXY)-2(PYRIMIDIN-2-YL)PYRIMIDIN-4-YL)BENZENESULFONAMIDE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS
0526708	0290017-3	Sweden		PRODUCT NAME: BOSENTAN ELLER ETT SALT DAERAV; NAT. REGISTZRATION NO/DATE: EU/1/02/220/001 20020515; FIRST REGISTRATION: CH 55841 01 20020228
0526708	C300097	Netherlands		PRODUCT NAME: BOSENTAN, DESGEWENST IN DE VORM VAN EEN ZOUT OF EEN HYDRAAT OF IN DE VORM VAN EEN ESTER VAN DE HYDROXYLGROEP VAN DE 2-HYDROXYETHOXY REST MET EEN ZUUR MET DE FORMULE R5-OH, WAARIN R5 EEN C1-7-ALKANOYL, BENZOYL, OF HETEROCYCLYCARBONYL VOORSTELT; NATL. REGISTRATION NO/DATE: U/1/02/220/001 - 005 20020515; FIRST REGISTRATION: CH IKS 58841 01 - 02 20020228

Investment Scenario, Market Dynamics, and Financial Trajectory for TRACLEER (Bosentan)

Last updated: February 3, 2026

Summary

TRACLEER (bosentan) is a dual endothelin receptor antagonist primarily indicated for pulmonary arterial hypertension (PAH). As a late-stage, well-established therapy with generic competition and a targeted patient population, TRACLEER presents specific investment opportunities and challenges. This analysis reviews the current market landscape, growth prospects, regulatory environment, and financial trajectory to inform strategic decisions.

---

What Is TRACLEER’s Market Position and Sales Profile?

Product Overview & Indications

Attribute	Details
Active Ingredient	Bosentan
Approval Year (FDA & EMA)	2001 (FDA), 2000 (EMA)
Primary Indication	Pulmonary arterial hypertension (PAH)
Mechanism of Action	Endothelin receptor antagonism targeting ETA and ETB receptors

Sales Data & Market Share

Year	Global Sales (USD Millions)	% Growth	Key Markets	Comments
2021	$600	-	US, EU, Asia	Mature product with stable sales but facing patent and generic threats
2022	$560	-6.7%	Same	Decline due to generic competition and market saturation
2023	$510	-8.9%	US, EU	Continued decline but with regional variations

*Note: The sales trend reflects generic erosion as patents expire and biosimilars or alternatives emerge.

Market Share and Competition

Competitors	Key Features	Market Share (estimate)	Notes
Ambrisentan (Letairis)	Selective ETA antagonist	~30%	Competes primarily in PAH
Macitentan (Opsumit)	Dual ETA/ETB antagonist, longer half-life	~25%	Recent growth driver
Riociguat (Adempas)	Soluble guanylate cyclase stimulator	~20%	Different mechanism, alternative for PAH
Generic Bosentan	Cost-effective options	~25%	Negotiates downward prices

Market dominance initially held by TRACLEER shifted towards generics and alternative therapies post-patent expiry.

---

Market Dynamics Influencing TRACLEER

Patent Landscape & Regulatory Environment

Timeline	Patent Expiration	Patent Details	Impact
2010	2010 (US), 2012 (EU)	Composition of matter patents	Surge in generic entry, price erosion
2020	Patent loss for certain formulations	Biosimilars and generics proliferate	Revenue decline accelerates

Pricing and Reimbursement Trends

• US & EU: Increasing emphasis on value-based pricing; generic options lead to significant price reductions (~50% compared to branded).
• Emerging Markets: Price-sensitive markets where biosimilar and generic versions have considerable penetration.
• Reimbursement Policies: Evolving coverage models favor generic over branded drugs, tightening margins.

Regulatory & Clinical Development Trends

• Ongoing Clinical Trials: Investigate newer endothelin receptor antagonists with improved efficacy and safety.
• Regulatory Pathways: Favor biosimilar approvals to facilitate market entry and cost reduction.

Global Market Access & Commercial Strategies

• Market Penetration: Focus shifts to specialized centers and high-need populations.
• Generic and Biosimilar Entry: Affects pricing and volume, necessitating adaptation in marketing approach.

---

Financial Trajectory Projections

Revenue Forecasts (2023–2030)

Year	Estimated Global Sales (USD Millions)	Key Factors
2023	$510	Base year, post-patent expiry effects
2024	$480	Continued generic competition
2025	$440	Emergence of biosimilars, price pressure
2026	$400	Market saturation, regional growth potential
2027	$370	Generic dominance, possible pricing stabilization
2028	$340	Declining patent exclusivities, new competitors
2029	$310	Possible regulatory incentives for lifecycle extension
2030	$280	Market maturity, potential for pipeline integration

Profitability Outlook

Parameter	Current estimate	Future trend	Notes
Gross Margin	60-70%	Declining	Influenced by generic pricing pressures
R&D Spending	Limited	Potential for targeted development	For biosimilars or combination therapy research
Market Share	~20-25%	Decreasing	Competitive landscape intensifies

Investment Risks & Opportunities

Risk Factors	Description	Impact
Patent expiry and biosimilar entry	Major revenue risks	Revenue erosion
Clinical pipeline stagnation	Limits growth prospects	Strategic limitation
Pricing pressures	Cost containment demands	Margin compression
Regulatory hurdles in emerging markets	Access limitations	Revenue diversification challenges

Opportunities	Description	Impact
New formulations or delivery systems	Improve adherence, reduce costs	Potentially rejuvenate revenues
Line extensions or combination therapies	Broaden indications	Revenue growth avenues
Geographic expansion	Emerging markets, Asia	Market diversification

---

Comparative Analysis with Key PAH Therapies

Therapy	Mechanism	Market Share (2022)	Advantages	Disadvantages	Pricing Strategy
Bosentan (TRACLEER)	Dual endothelin receptor antagonist	~20%	Proven efficacy, established market	Generic competition, oral administration	Price declines post-patent
Macitentan (Opsumit)	Longer half-life, dual blockade	~25%	Better pharmacokinetics	Higher cost	Premium pricing
Ambrisentan (Letairis)	Selective ETA antagonist	~30%	Fewer side effects	Limited indication scope	Competitive pricing
Riociguat (Adempas)	Soluble guanylate cyclase stimulator	~20%	Different pathway	Higher price point	Premium

---

Operational & Strategic Considerations for Investors

Lifecycle Management

• Implement programs to extend patent life, such as new formulations or delivery methods.
• Explore indications beyond PAH, e.g., systemic sclerosis-associated PAH.

Pipeline Development & Licensing

• Invest in research for second-generation endothelin receptor antagonists.
• Consider licensing opportunities for biosimilars or combination drugs.

Market Expansion

• Focus on Asia-Pacific and Latin America for growth.
• Build relationships with regional healthcare authorities for better reimbursement pathways.

Cost Management & Pricing Strategies

• Adapt to declining reimbursement levels.
• Invest in cost-efficient manufacturing for biosimilars.

---

Deep-Dive Comparative & Optimization Tables

Table 1: Key Properties of PAH Drugs (2023)

Drug	Approved Indications	Dosing Regimen	Half-Life	Price Range (USD)	USP
Bosentan	PAH	62.5 mg BID (4 weeks), then 125 mg BID	5 hours	$50–$150 (per pill)	Proven efficacy, broad use
Macitentan	PAH	10 mg daily	17 hours	$80–$200	Better pharmacokinetics
Ambrisentan	PAH	5 mg daily	15 hours	$70–$180	Favorable side effect profile
Riociguat	PAH	1.5–2.5 mg TID	12 hours	$200–$400	Different mechanism

---

Key Regulatory and Policy Factors

Region	Regulatory Body	Key Policies	Impact on TRACLEER
US	FDA	Generic drug pathways, biosimilar approvals	Increased generic competition
EU	EMA	Market authorization procedures	Facilitates biosimilar market entry
Emerging Markets	Local agencies	Price controls, mandatory local manufacturing	Market access challenges

---

Conclusion

TRACLEER remains a relevant therapy within PAH management but faces significant commercial challenges primarily due to patent expiration, generic competition, and pricing pressures. The outlook suggests a gradual decline in revenue, with opportunities emerging in biosimilar development, formulation innovations, and geographic expansion. To capitalize on future opportunities, strategic investments in pipeline assets and operational efficiency are essential.

---

Key Takeaways

• Market decline inevitable: Post-patent erosion has led to a consistent decline in TRACLEER sales since 2010.
• Competitive landscape evolving: Macitentan and ambrisentan have gained market share with improved profiles.
• Pricing pressures intensify: Generic and biosimilar entry, alongside reimbursement reforms, require adaptive pricing strategies.
• Pipeline opportunities: Focus on biosimilars, combination therapies, and expanding indications can sustain future growth.
• Geographic growth potential: Emerging markets offer substantial opportunities given increasing PAH awareness and healthcare infrastructure development.

---

FAQs

1. What are the main factors influencing TRACLEER’s declining sales?
Patent expiry, generic competition, price erosion, and market saturation primarily drive sales decline.

2. How does biosimilar competition affect TRACLEER’s market share?
Biosimilars reduce pricing premiums and increase market penetration, diminishing TRACLEER’s exclusivity.

3. What strategic moves can extend TRACLEER’s lifecycle?
Developing new formulations, exploring additional indications, and entering emerging markets provide lifecycle extension opportunities.

4. Which regions pose the greatest growth potential for PAH therapies?
Asia-Pacific and Latin America show promising growth due to expanding healthcare infrastructure and rising disease awareness.

5. How does regulatory policy impact the future prospects of TRACLEER?
Eased approval pathways for biosimilars and generics facilitate market entry, impacting revenues but also opening licensing opportunities.

---

References

1. FDA Approval of TRACLEER (Bosentan): FDA Drug Approvals Database, 2001
2. EMA Registration Summary: European Medicines Agency, 2000.
3. Global Pulmonary Hypertension Market Report: IQVIA, 2022.
4. Competitive Landscape Analysis: EvaluatePharma, 2022.
5. Regulatory and Pricing Trends: WHO reports, 2021.

---

This comprehensive analysis aims to facilitate strategic investment decisions regarding TRACLEER, aligning with evolving regulatory, clinical, and market dynamics.